Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24793375 | 1.00 | NCF1 (0.33) | NCF1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL21941844 | 0.85 | NCF1 (0.32) | NCF1CHRM2CHRM1CHRM3 | |
| SCHEMBL19476557 | 0.83 | NCF1 (0.35) | NCF1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL20028737 | 0.83 | NCF1 (0.35) | NCF1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL20028719 | 0.83 | NCF1 (0.35) | NCF1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL24428763 | 0.81 | NCF1 (0.34) | NCF1CHRM2CHRM1CHRM3 | |
| SCHEMBL20028734 | 0.80 | SMN1; SMN2 (0.41) | NCF1KDM4EGLA | |
| SCHEMBL20028721 | 0.80 | SMN1; SMN2 (0.41) | NCF1KDM4EGLA | |
| SCHEMBL21667887 | 0.79 | MAPK1 (0.37) | NCF1KDM4E | |
| SCHEMBL21667891 | 0.79 | MAPK1 (0.37) | NCF1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | NCF1 1388/4885CHRM2 3978/4885CHRM1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.